FN-1501

Generic Name: FN-1501

Brand Names: Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅N_₉O

CAS Number: 1429515-59-2

Unique Ingredient Identifier: 6MC966B505

Background: Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication: Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions: Transplanted Organ Rejection

Associated Therapies: -

Clinical Trials

Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Sirolimus Oral Product
Drug: Mycophenolate Mofetil

First Posted Date: 2018-07-11

Last Posted Date: 2021-04-26

Lead Sponsor: Institute for Clinical and Experimental Medicine

Target Recruit Count: 238

Registration Number: NCT03582878

Locations: 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Czechia

Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)

Phase 2

Conditions: Lupus Nephritis

Interventions: Other: Mesenchymal stem cells
Drug: Mycophenolate Mofetil
Drug: Placebo of Mycophenolate Mofetil
Other: Placebo of Mesenchymal stem cells

First Posted Date: 2018-07-09

Last Posted Date: 2018-07-10

Lead Sponsor: Lingyun Sun

Target Recruit Count: 230

Registration Number: NCT03580291

Locations: 🇨🇳
The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan

Completed

Conditions: Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant

First Posted Date: 2018-05-08

Last Posted Date: 2018-05-08

Lead Sponsor: Hikma Pharmaceuticals LLC

Target Recruit Count: 12

Registration Number: NCT03517982

Locations: 🇯🇴
Prince Hamza Hospital, Amman, Jordan

Tolerance by Engaging Antigen During Cellular Homeostasis

Phase 1

Active, not recruiting

Conditions: Renal Transplantation
Renal Transplant Recipient
Kidney Transplantation

Interventions: Biological: Donor-derived Mesenchymal Stromal Cells
Drug: alemtuzumab
Drug: belatacept
Drug: sirolimus
Drug: mycophenolate mofetil
Drug: mycophenolate acid
Drug: prednisone

First Posted Date: 2018-04-20

Last Posted Date: 2024-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT03504241

Locations: 🇺🇸
Duke University Health System, Durham, North Carolina, United States

CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Not Applicable

Terminated

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Cyclophosphamide
Drug: Methylprednisolone
Drug: Prednisone
Drug: Mycophenolate Mofetil

First Posted Date: 2018-04-10

Last Posted Date: 2021-07-21

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 49

Registration Number: NCT03492255

Locations: 🇧🇷
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil

Disease-Modifying Treatments for Myasthenia Gravis

Completed

Conditions: Neurological Disorder
Autoimmune Diseases

Interventions: Drug: Azathioprine
Drug: Mycophenolate Mofetil

First Posted Date: 2018-04-06

Last Posted Date: 2021-02-03

Lead Sponsor: Duke University

Target Recruit Count: 167

Registration Number: NCT03490539

Locations: 🇨🇦
University of Alberta Hospital, Faculty of Medicine, Edmonton, Alberta, Canada
🇺🇸
University at Buffalo, SUNY, Buffalo, New York, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 16 locations

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3

Active, not recruiting

Conditions: Lymphoma
Myelodysplasia
Plasma Cell Disorder
Acute Myeloid Leukemia
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myeloproliferative Disorder
Myelofibrosis

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total Body Irradiation
Drug: Tacrolimus
Drug: cellcept
Drug: g-csf
Procedure: Peripheral Blood Transplant

First Posted Date: 2018-03-29

Last Posted Date: 2024-07-23

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 21

Registration Number: NCT03480360

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic-Myeloproliferative Diseases
Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Acute Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorder
Non Hodgkin Lymphoma

Interventions: Radiation: Total Body Irradiation
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Drug: Tocilizumab
Drug: Filgrastim

First Posted Date: 2018-02-15

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT03434730

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Early Phase 1

Completed

Conditions: Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-02-08

Last Posted Date: 2020-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT03426969

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants

Phase 4

Completed

Conditions: Hypertrophy, Left Ventricular

Interventions: Drug: Everolimus
Drug: Mycophenolate mofetil
Drug: Tacrolimus

First Posted Date: 2018-01-30

Last Posted Date: 2021-01-08

Lead Sponsor: Edoardo Melilli

Target Recruit Count: 20

Registration Number: NCT03415750

Locations: 🇪🇸
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy